Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy

High ERβ/HER oncogenic signaling defines lung tumors with an aggressive biology. We previously showed that combining the anti-estrogen fulvestrant with the pan-HER inhibitor dacomitinib reduced ER/HER crosstalk and produced synergistic anti-tumor effects in immunocompromised lung cancer models, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Almotlak, Abdulaziz A., Farooqui, Mariya, Soloff, Adam C., Siegfried, Jill M., Stabile, Laura P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745184/
https://www.ncbi.nlm.nih.gov/pubmed/35008514
http://dx.doi.org/10.3390/ijms23010081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745184/
https://www.ncbi.nlm.nih.gov/pubmed/35008514
http://dx.doi.org/10.3390/ijms23010081

Ejemplares similares